Skip to main content
OpenTrials
Completed

NCT Number: NCT02146157

Trial of an Herb and Mineral Combination Product on Fasting Glucose in Adults at Risk for Developing Diabetes

This is a multi-center, randomized, double-blind, placebo-controlled study in approximately 104 subjects (52 per group) to evaluate the effectiveness of an herb and mineral combination product on fasting serum glucose levels in subjects with impaired fasting glucose. The study consists of 5 visits: a Screening visit, followed by a Baseline visit (at which eligible subjects will be randomized to product to consume throughout the 12-week supplementation period), followed by Supplementation period visits at 3, 6 and 12 weeks after baseline.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Radiant Research, Chicago, Illinois, United States

Loading trial locations.

About this study

The target population of this clinical trial is otherwise healthy, pre-diabetic adults who present with impaired fasting glucose.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be male or female, at least 18 years of age
  • If age ≥45 years, must have a body mass index ≥ 25 kg/m2
  • If age <45 years, must have a body mass index ≥ 25 kg/m2 AND present with at least one additional risk factors for developing diabetes.
  • Agree to use contraception throughout study period, unless postmenopausal or surgically sterile (women only)
  • Be able to understand the nature and purpose of the study including potential risks and side effects
  • Be willing to consent to study participation and to comply with study requirements
  • Have a finger stick fasting blood glucose between 105 and 140 mg/dL and a serum fasting glucose between 100 and 125 mg/dL, measured at screening

Exclusion criteria

  • Have diabetes (type I or II) or an HBA1c measurement >6.5% at any time in the past or at the screening visit
  • Have been taking within 2 weeks of screening any dietary supplement including vitamin and mineral complexes; herbal supplements; fish oil; fiber supplements; or any herbal ingredient/product that significantly affects glucose metabolism
  • Have been taking within 4 weeks of screening any prescription or over-the-counter (OTC) medication that significantly affects glucose metabolism, including but not limited to, sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, Inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors), systemic corticosteroids
  • Daily use of non-steroidal anti-inflammatory drugs (NSAIDS) (daily baby aspirin use and continuous use of NSAIDS for 3 days or less for acute aches and pains are acceptable)
  • Any co-morbidity or treatment that could, in the opinion of the investigator, preclude the subject's ability to successfully and safely complete the study or that may confound study outcomes
  • Anticipated changes in dietary patterns or physical activity levels during the study, including attempts at body weight reduction
  • Eating disorder
  • Polycystic ovary syndrome
  • Known allergies or intolerance to any substance in the study product
  • Are pregnant or breastfeeding women
  • History of alcohol, drug, or medication abuse
  • Have participated in another study with any investigational product within 1 month of screening
  • Had a recent (<3 months) gastrointestinal surgery or any planned surgery during the clinical study

Treatment and study plan

herb and mineral combination product

Dietary Supplement

herb and mineral product containing cinnamon, turmeric and holy basil

Placebo

Dietary Supplement

Placebo of herb and mineral product containing cinnamon, turmeric and holy basil

Primary outcomes

  1. Change from Baseline in fasting blood glucose

    Time frame: Day 84

    Fasting glucose will be measured on serum samples obtained at screening (to be used as baseline value) and at day 84

Secondary outcomes

  1. Change from Baseline in fasting serum glucose

    Time frame: Day 42

    Fasting glucose will be measured on serum samples obtained at screening (to be used as baseline value) and at day 42

  2. Change from Baseline in fasting blood glucose

    Time frame: Day 21

    Fasting glucose will be measured on serum samples obtained at screening (to be used as baseline value) and at day 21

  3. Change from Baseline in HbA1c

    Time frame: Day 84

    Glycosylated hemoglobin (HbA1c) will be measured on whole blood samples obtained at screening and at day 84.

  4. Change from Baseline in fasting lipids

    Time frame: Day 84

    Total cholesterol, high-density lipoprotein, low-density lipoprotein, very low-density lipoprotein, and triglycerides will be measured on serum samples obtained at screening and at day 84 using a standard lipid panel.

  5. Change from Baseline in fasting lipids

    Time frame: Day 42

    Total cholesterol, high-density lipoprotein, low-density lipoprotein, very low-density lipoprotein, and triglycerides will be measured on serum samples obtained at screening and at day 42 using a standard lipid panel.

  6. Change from Baseline in fasting lipids

    Time frame: Day 21

    Total cholesterol, high-density lipoprotein, low-density lipoprotein, very low-density lipoprotein, and triglycerides will be measured on serum samples obtained at screening and at day 21 using a standard lipid panel.

  7. Change from Baseline in BMI

    Time frame: Day 84

    Body mass index

  8. Change from Baseline in waist-to-hip ratio

    Time frame: Day 84

Sponsors and collaborators

Lead sponsor

NewChapter, Inc.

Industry

Collaborators

  • Procter and Gamble

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled Trial to Assess Efficacy and Tolerability of an Herb and Mineral Combination Product on Fasting Glucose in Adults at Risk for Developing Diabetes

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
May 23, 2014
Registry last updated
Oct 14, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.